Dynavax to Present Data on Phase 2 Clinical Trial of Hepatitis B Vaccine at ICAAC

BERKELEY, Calif., Oct 20, 2004 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) announced that safety and efficacy data from the company's Phase 2 clinical trial of its ISS-based Hepatitis B vaccine compared to GlaxoSmithKline's Engerix-B® vaccine will be presented in a late-breaker poster session at the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC. The data will be presented by Scott A. Halperin, M.D., of Dalhousie University, Halifax, Nova Scotia, Canada and Daniel Levitt, M.D., Ph.D., vice president and chief medical officer, Dynavax.

The poster is entitled, "Hepatitis B Virus Surface Antigen (HBV) Co- administered with an Immunostimulatory Phosphorothioate Oligonucleotide (HBV- ISS) Achieves Protective Antibody Levels More Quickly and with Fewer Doses than a Licensed Hepatitis B Vaccine."

The poster session is scheduled for Saturday, October 30th, 2004, 3:00- 4:30 p.m., in Exhibit Hall DE of the Washington Convention Center. The Dynavax poster number is G-557A. The poster will be available on the ICAAC website at the time of the poster session.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. ISS are being developed in three separate indications: a ragweed allergy program and a Hepatitis B vaccine program in late stage clinical development, and an asthma program that just completed a Phase II exploratory trial.

Dynavax cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to plans to advance its clinical programs and demonstrate the potential of its ISS technology. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "slated," "goal" and similar expressions are intended to identify forward- looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Dynavax that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Dynavax's business including, without limitation, risks relating to: the progress and timing of its clinical trials; difficulties or delays in developing, testing, obtaining regulatory approval of, producing and marketing its products; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; its ability to obtain additional financing to support its operations; its ability to maintain effective financial planning and internal controls; and other risks detailed in the "Risk Factors" section of Dynavax's Annual Report on Form 10-K filed on June 30, 2004, and in the section titled "Additional Factors That May Affect Future Results" within Dynavax's quarterly report on Form 10-Q filed on August 9, 2004. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Dynavax undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

SOURCE Dynavax Technologies Corporation
Jane Green, Vice President, Corporate Communications of Dynavax Technologies Corporation, 510-665-4630, or jgreen@dynavax.com

http://www.dynavax.com